Olaf Strauß

Olaf Strauß

Auto-generated profile, based on publicly available information

Olaf Strauß

Experimental Ophthalmology, Department of Ophthalmology Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität, Berlin Institute of Health, Humboldt‐University Berlin Germany

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2008 in Graefe's Archive for Clinical and Experimental Ophthalmology
Verified
Journal Article
Closed access
PDF file
SWSönke Wimmers
Sönke Wimmers
LCLinn Coeppicus
Linn Coeppicus
RRRita Rosenthal
Rita Rosenthal
OSOlaf Strauß
Olaf Strauß

3 April 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Ahmad Samir AlfaarAhmad Samir Alfaar
Ahmad Samir Alfaar
YYYacoub A Yousef
Yacoub A Yousef
MWMatthew W. Wilson
Matthew W. Wilson
OHOmneya Hassanain
Omneya Hassanain
VKVinodh Kakkassery
Vinodh Kakkassery
OSOlaf Strauß
Olaf Strauß
This epidemiological study examined ocular and orbital lymphomas in the United States from 1995 to 2018, using data from the North American Association of Central Cancer Registries database of 87,543 patients with ocular and adnexal malignancies. We identified 17,878 patients (20.4%) with ocular and orbital lymphomas, with an age-standardized incidence rate (ASIR) of 2.6 persons per million (ppm). The incidence was the highest in the orbit (ASIR = 1.24), followed by the conjunctiva (ASIR = 0.57). Non-Hodgkin B-cell lymphoma was the most prevalent subtype (85.4%), particularly marginal-zone lymphoma (45.7%). Racial disparities were noted, with Asia–Pacific Islanders showing the highest incidence (orbit, 1.3 ppm). The incidence increased significantly from 1995 to 2003 (Average Percent Change, APC = 2.1%) but declined thereafter until 2018 (APC = − 0.7%). 5-year relative survival (RS) rates varied, with the highest rate for conjunctival lymphoma (100%) and the lowest for intraocular lymphoma (70.6%). Survival rates have generally improved, with an annual increase in the 5-year RS of 0.45%. This study highlights the changing epidemiological landscape, pointing to initial increases and subsequent decreases in incidence until 2003, with survival improvements likely due to advancements in treatment. These findings underscore the need for further research to investigate the root causes of these shifts and the declining incidence of ocular lymphoma.

1 September 2020 in Graefe's Archive for Clinical and Experimental Ophthalmology
Verified
Journal Article
Open access
PDF file
Ahmad Samir AlfaarAhmad Samir Alfaar
Ahmad Samir Alfaar
ASAnas M. Saad
Anas M. Saad
MKMahmoud Tawfik KhalafAllah
Mahmoud Tawfik KhalafAllah
OEOmneya Ezzat Elsherif
Omneya Ezzat Elsherif
MOMoataz Hamed Osman
Moataz Hamed Osman
OSOlaf Strauß
Olaf Strauß
Purpose: The eye and its adnexal structures can give rise to first or consecutive primary malignancies or to encounter metastasis. Our aim was to define the characteristics of the second primary neoplasms affecting the eye and its adnexa and find the risk modifying factors for them after malignancies elsewhere in the body. Methods: We have queried the Surveillance, Epidemiology and End-Results “SEER”-9 program of the National Cancer Institute for the malignancies of the eye and its adnexa that occurred between 1973 and 2015. The malignancies were ordered chronologically according to their incidence: first or second primary malignancies. The tumors were classified according to ICD-O-3 classification. Standardized incidence ratios (SIR) and survival probabilities were calculated for subgroups. Results: Among 3,578,950 cancer patients, 1203 experienced a second malignancies of the eye and its adnexa. The first malignancy was diagnosed between 50 and 69 years of age in 58.94% of them. The eyelid showed 280 events, while 50 in lacrimal gland, 181 in the orbit, 21 in the overlapping lesions, 15 in optic nerve, 148 in the conjunctiva, 9 in the cornea, 6 in the Retina, 379 in the choroid, and 93 in the ciliary body. The SIR of a second malignancy after a prior non-Hodgkin lymphoma was 2.42, and in case of previous skin carcinomas it was 3.02, melanoma of skin, and 2.13 and 1.58 in oral cavity/pharynx malignancies. The second ocular and adnexal neoplasms increased steadily over the 5-year periods on contrary to first primary neoplasms. The survival of patients affected with first ocular and adnexal neoplasms was significantly higher than those with second ocular and adnexal neoplasms. On the other side, second primary ocular and adnexal tumors showed a better survival than second primary malignancies elsewhere. Conclusions: The epidemiological differences between first and second ocular and adnexal primaries suggest different underlying mechanisms. Careful ocular examination should be integrated in the long-term follow-up plan of cancer patients. Special attention should be given to patients with non-Hodgkin’s lymphoma and melanoma as first primary.

5 July 2024 in Ophthalmic Epidemiology
Verified
Journal Article
Closed access
PCPiotr Chlad
Piotr Chlad
VKVinodh Kakkassery
Vinodh Kakkassery
AWArmin Wolf
Armin Wolf
CMChristina V. Miller
Christina V. Miller
OSOlaf Strauss
Olaf Strauss
Ahmad Samir AlfaarAhmad Samir Alfaar
Ahmad Samir Alfaar
PurposeThis study aims to evaluate the epidemiological patterns, treatment strategies, and survival outcomes of conjunctival malignancies in Germany between 2009 and 2019.MethodsA total of 1,532 cases were analyzed, with the crude incidence rate calculated. The survival rates were investigated using life tables and Cox regression analysis.ResultsThe overall incidence rate was 1.7 per million. Incidence rates varied across age groups, peaking in the 75+ age group. Carcinomas (43%), melanomas (30%), and lymphomas (20%), were the most prevalent malignancies. Of the total cases with reported treatment, surgical intervention was undertaken in 64.5% of the patients. The 5-year overall survival rates were 90.4% for lymphomas, 73.8% for melanomas, and 72.9% for carcinomas. Age at diagnosis emerged as a significant prognostic factor in the Cox regression analysis.ConclusionsThis study provides the first population-based incidence data on conjunctival malignancies in Germany, noting a generally low incidence with survival rates comparable to other regions. The findings underscore the importance of consistent reporting and further research into risk factors for a deeper understanding of these malignancies. The study calls for improved reporting systems and further investigations into genetic factors and targeted prevention strategies for high-risk groups.

9 March 2026 in PLOS ONE
Verified
Journal Article
Open access
PDF file
IPInga-Marie Pompös
Inga-Marie Pompös
DPDietrich Polenz
Dietrich Polenz
NKNorbert Kociok
Norbert Kociok
SWSilvia Winkler
Silvia Winkler
OSOlaf Strauß
Olaf Strauß
Early menopause increases the risk for age-related macular degeneration (AMD), the most common cause of vision loss in industrialized countries. The supplementation with estradiol reduces the risk in these cases and suggesting that estradiol deficiency is a mediator of the risk association. We investigated rat models of estradiol deficiency mimicking either biological ageing (22 months of age) or early menopause by ovariectomy and age of 22 months. Serum analysis of gonadal hormones in both models showed the expected reduction in estradiol levels compared to 6 months old controls but also increases in progesterone, corticosterone and dehydroepiandrosterone sulfate (DHEA-S). Comparing the two estradiol deficiency models, we found no differences except for DHEA-S that were reduced in ovariectomized rats. The hormone status was associated with degenerative changes in the retina with higher activity of mononuclear phagocytes and p16/p21-dependent senescence. Mainly the estrogen receptor beta (ERβ) expressing cells were affected by estradiol deficiency: ganglion cells, cells of the inner nuclear layer (INL) and retinal pigment epithelial cells. An exception are photoreceptors that were ERβ negative, showed stronger degeneration in ovariectomized rats compared to sham treated animals. We conclude that either biological or ovariectomy induced estradiol deficiency might not cause but rather promote mechanisms that lead to AMD. The phenotype depends on a broader spectrum of altered hormones than on estradiol alone. Photoreceptor degeneration and cellular senescence that were ERβ independent in ovariectomized rats suggest non-estradiol effects to increase AMD risk by early menopause.

11 June 2026 in Glia
Verified
Journal Article
Closed access
ASAlissa Schaefer
Alissa Schaefer
OBOliver Bludau
Oliver Bludau
ASAndjela Sekulic
Andjela Sekulic
SASena Altunok
Sena Altunok
SMStefan Mergler
Stefan Mergler
NRNadine Reichhart
Nadine Reichhart